Time filter

Source Type

Zürich, Switzerland

Rebollo I.R.,Ecole Polytechnique Federale de Lausanne | Sabisz M.,Ecole Polytechnique Federale de Lausanne | Baeriswyl V.,Ecole Polytechnique Federale de Lausanne | Baeriswyl V.,Covagen Inc. | Heinis C.,Ecole Polytechnique Federale de Lausanne
Nucleic Acids Research

High-throughput sequencing was previously applied to phage-selected peptides in order to gain insight into the abundance and diversity of isolated peptides. Herein we developed a procedure to efficiently compare the sequences of large numbers of phageselected peptides for the purpose of identifying target-binding peptide motifs. We applied the procedure to analyze bicyclic peptides isolated against five different protein targets: sortase A, urokinase-type plasminogen activator, coagulation factor XII, plasma kallikrein and streptavidin. We optimized sequence data filters to reduce biases originating from the sequencing method and developed sequence correction algorithms to prevent identification of false consensus motifs. With our strategy, we were able to identify rare target-binding peptide motifs, as well as to define more precisely consensus sequences and sub-groups of consensus sequences. This information is valuable to choose peptide leads for drug development and it facilitates identification of epitopes. We furthermore show that binding motifs can be identified after a single round of phage selection. Such a selection regimen reduces propagationrelated bias and may facilitate application of phage display in non-specialized laboratories, as procedures such as bacterial infection, phage propagation and purification are not required. © The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research. Source

Covagen Inc. | Date: 2010-08-24

The present invention relates to new IL-17 inhibiting polypeptides, corresponding fusion proteins, compositions and medical uses thereof.

Covagen Inc. | Date: 2013-09-19

The present invention relates to a polypeptide inhibiting the activity of glycosylated IL-17A, wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X

Covagen Inc. | Date: 2012-04-24

The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X

News Article | December 1, 2014
Site: www.fiercebiotech.com

Johnson & Johnson's ($JNJ) plan to grow its pipeline with deal-scouting outposts around the globe is beginning to pay off, as the drugmaker's London lookout has brought in what could be a promising approach to rheumatoid arthritis. Through its Janssen subsidiary, J&J has licensed some bone-protective compounds from U.K. biotech Modern Biosciences, handing over an undisclosed up-front payment and promising as much as £176 million ($277 million) in milestones. Modern Biosciences says its oral candidates employ a novel mechanism of action to treat arthritis, at once reducing the inflammation at the heart of RA and protecting bones from the disease's damaging effects. Neither company is disclosing just how many compounds are covered in the deal, saying only that the most advanced of the treatments is slated to enter Phase I in 2015. Modern Biosciences makes its money by in-licensing discovery projects, running proof-of-principle studies and then out-licensing them to drug developers. The London-headquartered outfit got its hands on the arthritis program through a 2007 deal with OsteoRX, a spinout of the University of Aberdeen, and the technology's promise drew a £2.4 million ($3.8 million) award from the publicly funded Innovate UK earlier this month. Along the way, J&J's London Innovation Center got involved. Launched last year, the outpost is part of J&J's new global network designed to find the academics, entrepreneurs and innovators at work on what could be tomorrow's blockbusters. The plan is to fan out and look to seed and incubate promising ideas, whether by licensing assets or helping build new companies, and J&J has stood up similar operations in Boston, San Francisco and Shanghai. And now that the RA deal is signed, the London Innovation Center is on tap to broker the collaboration between Janssen and Modern Biosciences, rolling forward with what both companies believe could be a novel approach to a common disease. "We are delighted to be working with Janssen to progress our novel series of compounds," Modern Biosciences CEO Sam Williams said in a statement. "MBS' compounds have unique characteristics compared to existing treatments for rheumatoid arthritis, and we believe Janssen is an ideal partner with which to take the molecules forward. This agreement demonstrates MBS' business model, which is to take early-stage assets from academia and advance them to a point of value inflection when they can be licensed to industry, generating a return for our stakeholders." Taking the pulse of partnering at BIO 2014 Related Articles: J&J partnering team now embedded in Shanghai hub, completing global network J&J snaps up Covagen and its protein-antibody fusion platform J&J Innovation shows off its new summer lineup of biotech deals

Discover hidden collaborations